Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477700 | 1.00 | HSP90AB1 (0.33) | HSP90AB1ATMALDH1A1POLBMAPT | |
| SCHEMBL12828064 | 1.00 | HSP90AB1 (0.33) | HSP90AB1ATMALDH1A1POLBMAPT | |
| SCHEMBL1477608 | 1.00 | HSP90AB1 (0.33) | HSP90AB1ATMALDH1A1POLBMAPT | |
| SCHEMBL1477610 | 1.00 | HSP90AB1 (0.33) | HSP90AB1ATMALDH1A1POLBMAPT | |
| SCHEMBL12749262 | 1.00 | HSP90AB1 (0.33) | HSP90AB1ATMALDH1A1POLBMAPT | |
| SCHEMBL1478169 | 0.86 | GAA (0.36) | ALDH1A1POLBMAPTKDM4E | |
| SCHEMBL12749257 | 0.86 | GAA (0.36) | ALDH1A1POLBMAPTKDM4E | |
| SCHEMBL1477813 | 0.86 | MAPK1 (0.33) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12749270 | 0.86 | MAPK1 (0.33) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1478158 | 0.77 | RXFP1 (0.32) | HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373261-B1 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7405310-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2008-07-29 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-6894177-B2 | Intermediate compounds of non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-05-17 | — | — | US | disclosed |
| US-6716850-B2 | ESPECIALLY N-(NITROGEN HETEROAR-2-YL)-SUBSTITUTED TETRAHYDROCYCLOPROPA(C)CHROMEN-1-UREAS AND THIOUREAS; TREATING HIV-1, PARTICULARLY A DRUG ESCAPE MUTANT. | MEDIVIR AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, TYMP, PNP | HSP90AB1 3147/4885ATM 3939/4885ALDH1A1 735/4885 |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | HSP90AB1 3587/4885ATM 4663/4885ALDH1A1 1540/4885 |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | HSP90AB1 3587/4885ATM 4663/4885ALDH1A1 1540/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | HSP90AB1 3384/4885ATM 4576/4885ALDH1A1 2705/4885 |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | HSP90AB1 4838/4885ATM 4389/4885ALDH1A1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.